Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates

Pharmacotherapy

Volumn 28, Issue 5 PART 1, 2008, Pages 667-677

  King, Amber E ^a   Umland, Elena M ^b  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Bisphosphonates; Diphosphonates; Jaw; ONJ; Osteonecrosis

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLINDAMYCIN; DOXYCYCLINE; ERYTHROMYCIN; ETIDRONIC ACID; GLUCOCORTICOID; IBANDRONIC ACID; METRONIDAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; PAMIDRONIC ACID; PARACETAMOL; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RISEDRONIC ACID; TILUDRONIC ACID; ZOLEDRONIC ACID;

BONE METASTASIS; BONE NECROSIS; BREAST CANCER; DENTAL CARE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGITIS; FEVER; HUMAN; HYPERCALCEMIA; INJECTION SITE PAIN; JAW DISEASE; LUNG CANCER; MULTIPLE MYELOMA; MYALGIA; NEPHROTOXICITY; PAGET BONE DISEASE; PHARMACIST; PROSTATE CANCER; RISK FACTOR; SHORT SURVEY;

ADMINISTRATION, ORAL; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; HUMANS; INFUSIONS, INTRAVENOUS; JAW DISEASES; OSTEONECROSIS;

EID: 42949142746     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.28.5.667     Document Type: Short Survey

References (71)

1. Merck & Co., Inc. Fosamax (alendronate sodium) package insert. Whitehouse Station, NJ; 2006.
2. Procter & Gamble Pharmaceuticals. Actonel (risedronate sodium) package insert. Cincinnati, OH; 2007.
3. Roche Laboratories. Boniva (ibandronate sodium tablets) package insert. Nutley NJ; 2006.
4. Roche Laboratories. Boniva (ibandronate sodium injection) package insert. Nutley NJ; 2007.
5. Novartis. Reclast (zoledronic acid) package insert. East Hanover, NJ; 2007.
6. Sanofi-Aventis. Skelid (tiludronate disodium) package insert. Bridgewater, NJ; 2006.
7. Procter & Gamble Pharmaceuticals. Didronel (etidronate disodium) package insert. Cincinnati, OH; 2005.
8. Novartis. Zometa (zoledronic acid) package insert. East Hanover, NJ; 2005.
9. Novartis. Aredia (pamidronate disodium) package insert. East Hanover, NJ; 2007.
10. Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007;65:369-76.
11. Wynn RL. Bisphosphonates, hypercalcemia of malignancy, and osteonecrosis of the jaw. Gen Dent 2005;53:392-5.
12. Woo SB, Hellstein JW, Kalmar JR. Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006;144:753-61.
13. Friedman PA. Agents affecting mineral ion homeostasis and bone turnover. In: Brunton LL, Lazo JS, Parker KL, eds. Goodman and Gilman's the pharmacological basis of therapeutics, 11th ed. New York: McGraw Hill 2006:1666-9.
14. Novak KK, ed. Drug facts and comparisons. 60th ed. St. Louis, MO: Wolters Kluwer Health, 2006.
15. Migliorati CA, Schubert MM, Peterson DE, Seneda LM. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone. Cancer 2005;104:83-93.
16. Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006;102:433-41.
17. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention and treatment. J Oral Maxillofac Surg 2005;63:1567-75.
18. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62:527-34.
19. Clarke BM, Boyette J, Vural E, Suen JY, Anaissie EJ, Stack BC. Bisphosphonates and jaw osteonecrosis: the UAMS experience. Otolaryngology 2007,136:396-400.
20. Farrugia MC, Summerlin DJ, Krowiak E, et al. Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonates. Laryngoscope 2006;116:115-20.
21. Thakkar SG, Isada C, Smith J, et al. Jaw complications associated with bisphosphonate use in patients with plasma cell dyscrasias. Med Oncol 2006;23:51-6.
22. Wutzl A, Eisenmenger G, Hoffman M, et al. Osteonecrosis of the jaws and bisphosphonate treatment in cancer patients. Wein Klin Wochenschr 2006;118:473-8.
23. Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005;23:8580-7.
24. Graziani F, Cei S, LaFerla F, Cerri E, Itro A, Gabriele M. Association between osteonecrosis of the jaws and chronic high-dosage intravenous bisphosphonates therapy. J Craniofac Surg 2006;17:876-9.
25. Dannemann C, Gratz KW, Riener MO, Zwahlen R. Jaw osteonecrosis related to bisphosphonate therapy: a severe secondary disorder Bone 2007;40:828-34.
26. Pires FR, Miranda A, Cardoso ES, et al. Oral avascular bone necrosis associated with chemotherapy and bisphosphonate therapy. Oral Dis 2005;11:365-9.
27. Zarychanski R, Elphee E, Walton P, Johnston J. Osteonecrosis of the jaw associated with Pamidronate therapy. Am J Hematol 2006;81:73-5.
28. Dimitrakopoulos I, Magopoulos C, Karaksis D. Bisphosphonate- induced avascular osteonecrosis of the jaws: a clinical report of 11 cases. J Oral Maxillofac Surg 2006;35:588-93.
29. Melo MD, Obeid G. Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy. J Am Dent Assoc 2005;136:1675-81.
30. Diego R, D'Orto O, Pagani D, et al. Bisphosphonate-associated osteonecrosis of the jaws: a therapeutic dilemma [online exclusive article]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007;103:e1-5. Available from http://dx.doi.org/10.1016/j.tripleo.2006.09.022.
31. Wang J, Goodger NM, Pogrel MA. Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 2003;61:1104-7.
32. Carter G, Goss AN, Doecke C. Bisphosphonates and avascular necrosis of the jaw: a possible association [letter]. Med J Aust 2005;182:413-15.
33. Viale PH, Lin A. Exposed bone in oral cavities. Clin J Oncol Nurs 2005;9:355-7.
34. Oltonia A, Achilli A, Lodi G, Demarosi F, Sardella A. Osteonecrosis of the jaws in patients treated with bisphosphonates. Minerva Stomatol 2005;54:441-5.
35. Olson KB, Hellie CM, Pienta KJ. Osteonecrosis of jaw in patients with hormone-refractory prostate cancer treated with zoledronic acid [online exclusive article]. Urology 2005;66:658.eI-3. Available from http://dx.doi.org/10.1016/j.urology.2005.03.028.
36. Sitters MA, Caldwell CS. Bisphosphonates, dental care and osteonecrosis of the jaws. Tex Dent J 2005;122:968-72.
37. Sarathy AP, Bourgeois SL, Goodell GG. Bisphosphonate-associated osteonecrosis of the jaws and endodontic treatment: two case reports. J Endod 2005;31:759-63.
38. Ficarra G, Beninati F, Rubino I, et al. Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment. J Clin Periodontol 2005;32:1123-8.
39. Katz H. Endodontic implications of bisphosphonate-associated osteonecrosis of the jaws: a report of three cases. J Endod 2005;31:831-4.
40. Marunick M, Miller R, Gordon S. Adverse oral sequelae to bisphosphonate administration. J Mich Dent Assoc 2005;87:44-50.
41. Merigo E, Manfredi M, Meleti M, Corradi D, Vescovi P. Jaw bone necrosis without previous dental extractions associated with the use of bisphosphonates (pamidronate and zoledronate): a four-case report. J Oral Pathol Med 2005;34:613-17.
42. Cope D. Clinical update: a nonhealing fractured mandible. Clin J Oncol Nurs 2005;9:685-7.
43. Markiewicz MR, Margarone JE, Campbell JH, Aguirre A. Bisphosphonate-associated osteonecrosis of the jaws. J Am Dent Assoc 2005;136:1669-74.
44. Pastor-Zuazaga D, Garatea-Crelgo J, Martino-Gorbea R, Etayo-Perez A, Sebastian-Lopez C. Osteonecrosis of the jaws and bisphosphonates: report of three cases [online exclusive article]. Med Oral Patol Oral Cir Bucal 2006;11:E76-9. Available from http://www.medicinaoral.com/medoralfree01/v11i1/ medoralv11i1p76.pdf.
45. Hansen T, Kunkel M, Weber A, Kirkpatrick CJ. Osteonecrosis of the jaws in patients treated with bisphosphonates-histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med 2006;35:155-60.
46. Hay KD, Bishop PA. Association of osteonecrosis of the jaws and bisphosphonate pharmacotherapy: dental implications. N Z Med J 2006;102:4-9.
47. Soileau KM. Oral post-surgical complications following the administration of bisphosphonates given for osteopenia related to malignancy. J Periodontol 2006;77:738-43.
48. Tsai WS, Haghighi K, Placa S. Bisphosphonate-induced osteonecrosis of the jaws: a case report and literature review. Gen Dent 2006;54:215-19.
49. Capalbo S, Delia M, Diomede D, et al. Jaw osteonecrosis associates with use of bisphosphonates and chemotherapy: paradoxical complication of treatment of bone lesions in multiple myeloma patients. Int J Hematol 2006;83:439-42.
50. Leite AF, Figueiredo PT, Melo NS, Acevedo AC, Cavalcanti MGP, Paula LM. Bisphosphonate-associated osteonecrosis of the jaws: report of a case and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006;102:14-21.
51. Braun E, Iacono VJ. Bisphosphonates: case report of nonsurgical periodontal therapy and osteochemonecrosis. Int J Periodontics Restorative Dent 2006;26:315-19.
52. Kademani D, Koka S, Lacy MQ, Rajkumar SV. Primary surgical therapy for osteonecrosis of the jaw secondary to bisphosphonate therapy. Mayo Clin Proc 2006;81:1100-3.
53. Nase JB, Suzuki JB. Osteonecrosis of the jaw and oral bisphosphonate treatment. J Am Dent Assoc 2006;137:1115-19.
54. Doyle-Lindrud S. Implications of androgen-deprivation therapy in patients with prostate cancer: a case study. Clin J Oncol Nurs 2006;10:565-6.
55. Battley J, Jayathissa S, Seneviratne E. Jaw osteonecrosis associated with bisphosphonates [case report]. N Z Med J 2006;119:112341.
56. Mortensen M, Lawson W, Montazem A. Osteonecrosis of the jaw associated with bisphosphonate use: presentation of seven cases and literature review. Laryngoscope 2007;117:30-4.
57. Curi MM, Cossolin GSI, Koga DH, et al. Treatment of avascular osteonecrosis of the mandible in cancer patients with a history of bisphosphonate therapy by combining bone resection and autologous platelet-rich plasma: report of 3 cases. J Oral Maxillofac Surg 2007;65:349-55.
58. Senel FC, Tekin US, Durmus A, Bagis B. Severe osteomyelitis of the mandible associated with the use of non-nitrogen-containing bisphosphonate (disodium clodronate): report of a case. J Oral Maxillofac Surg 2007;65:562-5.
59. Brooks JK, Gilson AJ, Sindler AJ, Ashman SG, Schwartz KG, Nikitakis NG. Osteonecrosis of the jaws associated with the use of risedronate: report of 2 new cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007;103:780-6.
60. Badros A, Weikel D, Salama A, et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 2006;24:945-52.
61. Dimopoulos MA, Kastritis E, Anagnostopoulos A, et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica 2006;91:968-71.
62. Zervas K, Verrou E, Teleioudis Z, et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol 2006;134:620-3.
63. Ruggiero S, Gralow J, Marx RE, et al. Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Pract 2006;2:7-14.
64. Celgene Corporation. Thalomid (thalidomide) package insert. Summit, NJ; 2005.
65. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-22.
66. Kyle RA, Yee GC, Somerfield MR, et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 2007;25:2464-72.
67. Drugtopics.com. Pharmacy facts and figures: top 200 brandname drugs by units in 2007. Available from www.drugtopics.com/drugtopics/data/ articlestandard/drugtopics/072008/491207/article.pdf. Accessed February 25, 2008.
68. American Dental Association Council on Scientific Affairs. Dental management of patients receiving oral bisphosphonates therapy: expert panel recommendations. J Am Dent Assoc 2006;137:1144-50.
69. Migliorati CA, Casiglia J, Epstein J, Jacobsen PL, Siegel MA, Woo S. Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper. J Am Dent Assoc 2005;136:1658-68.
70. Cheng A, Mavrokokki A, Carter G, et al. The dental implications of bisphosphonates and bone disease. Aust Dent J 2005;50(suppl 2):S4-13.
71. Reszka AA, Rodan GA. Nitrogen-containing bisphosphonate mechanism of action. Mini Rev Med Chem 2004;4:711-19.